Seres Therapeutics Inc To Discuss Ser-109 Commercial Strategy Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Seres Therapeutics Investor Call. I would now like to turn the call over to Eric Shaff, Seres Therapeutics' CEO. Please go ahead.
Thank you, operator, and good morning, everyone. I will begin on Slide 2 of our posted presentation. .
I'd like to remind you that we'll be making forward-looking statements today. Please refer to our SEC filings for additional information.
Moving to Slide 3. I'm excited to be joined by a number of my colleagues here today as well as the leading academic and practicing gastroenterologist, Professor Carl Crawford. Dr. Crawford is an Assistant Professor of Clinical Medicine with Weill Cornell Medicine and has many years of experience managing patients with recurrent CDI. Dr. Crawford will provide an overview of the disease from a practice and clinician's perspective and his view of the specific need for new therapies.
Following Dr. Crawford, Dr. Lisa von Moltke, Seres'
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
